Amgen, Inc. (OQ:AMGN)

Aug 03, 2020 07:30 am ET
Members Of The COVID R&D Alliance And Quantum Leap Healthcare Collaborative Enroll First Patients In I-SPY COVID Trial
SAN FRANCISCO, Aug. 3, 2020 /PRNewswire/ -- Today, members of the COVID R&D Alliance AbbVie, Inc. (NYSE: ABBV), Amgen Inc. (NASDAQ: AMGN), and Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) announced the first patients enrolled in the I-SPY COVID Trial (Investigation of Serial Studies to Predict Your COVID Therapeutic Response with Biomarker Integration and Adaptive Learning) clinical trial. The I-SPY COVID Trial will evaluate the efficacy of cenicriviroc, a chemokine (CCR2 and CCR5) dual-receptor antagonist, Otezla® (apremilast), a PDE4 inhibitor, and Firazyr® (icatibant injection), a brady...
Jul 30, 2020 07:59 am ET
Amgen Commences Exchange Offers For Certain Series Of Outstanding Senior Notes From Exchange Eligible Holders
THOUSAND OAKS, Calif., July 30, 2020 /PRNewswire/ -- Amgen Inc. (NASDAQ: AMGN) announced today the commencement of nine separate private offers to exchange (each, an "Exchange Offer" and, collectively, the "Exchange Offers") certain specified series of its outstanding senior notes (collectively, the "Old Notes") for a combination of a cash payment and new Senior Notes due 2053 (the "New Notes")....
Jul 28, 2020 04:01 pm ET
Amgen Reports Second Quarter 2020 Financial Results
THOUSAND OAKS, Calif., July 28, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2020. ...
Jul 23, 2020 05:00 pm ET
Amgen Announces Webcast Of 2020 Second Quarter Financial Results
THOUSAND OAKS, Calif., July 23, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Tuesday, July 28, 2020, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team....
Jul 23, 2020 04:15 pm ET
Amgen Announces 2020 Third Quarter Dividend
THOUSAND OAKS, Calif., July 23, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.60 per share dividend for the third quarter of 2020. The dividend will be paid on September 8, 2020, to all stockholders of record as of the close of business on August 17, 2020....
Jul 23, 2020 04:00 pm ET
Amgen Appoints Amy E. Miles To Board Of Directors
THOUSAND OAKS, Calif., July 23, 2020 /PRNewswire/ -- Amgen today announced the appointment of Amy E. Miles to its Board of Directors, effective July 23, 2020.  Ms. Miles will serve as a member of the Board's Audit Committee and Governance and Nominating Committee.  Following the appointment of Ms. Miles, the Board will be composed of 12 directors, 11 of whom are independent....
Jul 21, 2020 09:00 am ET
Amgen Foundation Awards Khan Academy An Additional $3 Million To Support Science Learning And Educational Equity Amid COVID-19
THOUSAND OAKS, Calif. and MOUNTAIN VIEW, Calif., July 21, 2020 /PRNewswire/ -- The Amgen Foundation today announced the renewal of a $3 million grant to Khan Academy to support several key learning initiatives, including virtual biology lessons; partnerships with school districts facing budget shortfalls; and a collaboration with LabXchange, a new online science learning platform launched by Harvard and the Amgen Foundation earlier this year....
Jul 12, 2020 10:00 pm ET
Amgen Announces Additional Investment In BeiGene
THOUSAND OAKS, Calif., July 12, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced an additional investment of approximately $421 million in BeiGene's registered direct offering of ordinary shares, which maintains Amgen's current pro rata ownership of BeiGene at approximately 20.3%.  This additional investment reflects Amgen's confidence in the progress the companies are making in their ongoing oncology collaboration in China, the world's second largest pharmaceutical market.  ...
Jul 01, 2020 11:50 am ET
Appeals Court Affirms Validity Of Enbrel® (etanercept) Patents Injunction Against Sandoz's Infringement Stands
THOUSAND OAKS, Calif., July 1, 2020 /PRNewswire/ -- Amgen today announced that the United States Court of Appeals for the Federal Circuit has held in Amgen's favor on the validity of two patents that describe and claim Enbrel® (etanercept) and methods for making it. ...
Jun 24, 2020 11:00 am ET
deCODE Genetics: Loss of Function Variant in FLT3 Strongly Increases the Risk of Autoimmune Thyroid Disease and Other Autoimmune Diseases
REYKJAVIK, Iceland, June 24, 2020 /CNW/ -- Scientists at deCODE genetics, a subsidiary of Amgen, and their collaborators from the Icelandic healthcare system, University of Iceland and the Karolinska Institute in Sweden, today publish a study in Nature, comparing over 30 thousand patients with autoimmune thyroid disease from Iceland and UK with 725 thousand controls. Autoimmune thyroid disease (AITD) is the most common autoimmune disease and is highly heritable. The scientists found 99 sequence variants that associate with autoimmune thyroid disease and 84 of those had not been associated wi...
Jun 24, 2020 11:00 am ET
deCODE Genetics: Loss of Function Variant in FLT3 Strongly Increases the Risk of Autoimmune Thyroid Disease and Other Autoimmune Diseases
REYKJAVIK, Iceland, June 24, 2020 /PRNewswire/ -- Scientists at deCODE genetics, a subsidiary of Amgen, and their collaborators from the Icelandic healthcare system, University of Iceland and the Karolinska Institute in Sweden, today publish a study in Nature, comparing over 30 thousand patients with autoimmune thyroid disease from Iceland and UK with 725 thousand controls. Autoimmune thyroid disease (AITD) is the most common autoimmune disease and is highly heritable. The scientists found 99 sequence variants that associate with autoimmune thyroid disease and 84 of those had not been associ...
Jun 22, 2020 04:00 pm ET
Amgen Is Supporting Advancement Of AMG 634 For Global Health Diseases In Developing Countries
THOUSAND OAKS, Calif., June 22, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced it is supporting the further study of AMG 634, a phosphodiesterase type 4 (PDE4) inhibitor, for the treatment of tuberculosis (TB) and erythema nodosum leprosum (ENL), an inflammatory cutaneous and systemic complication of leprosy.  Amgen acquired AMG 634 (formerly CC-11050) as part of its acquisition of Otezla® (apremilast) from Celgene in 2019. AMG 634 is currently in Phase 2 studies led by The Aurum Institute NPC (TB study) and The Leprosy Mission Nepal (ENL study)....
Jun 18, 2020 04:00 pm ET
Amgen To Present At The BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference
THOUSAND OAKS, Calif., June 18, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference at 4:00 p.m. ET on Tuesday, June 23, 2020. Elliott Levy, senior vice president of R&D Strategy and Operations at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for 90 days following the event....
Jun 05, 2020 04:00 pm ET
Amgen To Present At The Goldman Sachs 41st Annual Global Healthcare Conference
THOUSAND OAKS, Calif., June 5, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 41st Annual Virtual Global Healthcare Conference on Wednesday, June 10, 2020 at 1:20 p.m. ET. Peter H. Griffith, executive vice president and chief financial officer, and David M. Reese, M.D., executive vice president of Research and Development at Amgen will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90...
May 29, 2020 08:00 am ET
Amgen Presents New AMG 510 Clinical Data Across Multiple Solid Tumors During ASCO20 Virtual Scientific Program
THOUSAND OAKS, Calif., May 29, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the CodeBreaK 100 clinical development program evaluating investigational AMG 510 (proposed INN sotorasib) in heavily pretreated patients with a range of KRAS G12C-mutant solid tumors. Updated Phase 1 data from patients with advanced colorectal cancer (CRC) and other selected solid tumors continued to demonstrate disease control activity, safety and tolerability. These data are being presented during the ASCO20 Virtual Scientific Program, May 29 – 31, 2020....
May 28, 2020 05:00 pm ET
Amgen To Present At The Jefferies 2020 Virtual Healthcare Conference
THOUSAND OAKS, Calif., May 28, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Jefferies 2020 Virtual Healthcare Conference at 4:00 p.m. ET on Tuesday, June 2, 2020.  David M. Reese, M.D., executive vice president of Research and Development at Amgen, will be leading the presentation. Live audio of the fireside chat can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for 90 days following the event....
May 26, 2020 05:00 pm ET
Amgen To Webcast Investor Meeting At 56th Annual Meeting Of The American Society Of Clinical Oncology (ASCO)
THOUSAND OAKS, Calif., May 26, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will host a webcast call for the investment community in conjunction with the ASCO20 Virtual Scientific Program on Friday, May 29, at 1:00 p.m. PT.  David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team and clinical investigators, will participate to discuss Amgen's oncology program, including data being presented on the Company's KRASG12C inhibitor sotorasib. ...
May 20, 2020 07:00 pm ET
Amgen Announces Voting Results Of Annual Meeting Of Stockholders
THOUSAND OAKS, Calif., May 20, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced voting results from the Company's Annual Meeting of Stockholders on May 20, 2020, held virtually this year due to the COVID-19 pandemic. More than 88 percent of outstanding shares were represented at the meeting....
May 13, 2020 05:00 pm ET
Amgen Showcases Oncology Pipeline At ASCO 2020
THOUSAND OAKS, Calif., May 13, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that data from its oncology pipeline and marketed portfolio will be presented during the ASCO20 Virtual Scientific Program taking place May 29 - 31, 2020. ...
May 12, 2020 09:00 am ET
Amgen To Present At The Bank Of America Merrill Lynch Virtual Global Healthcare Conference
THOUSAND OAKS, Calif., May 12, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Virtual Global Healthcare Conference at 1:40 p.m. ET on Thursday, May 14.  Peter H. Griffith, executive vice president and chief financial officer, and Murdo Gordon, executive vice president of Global Commercial Operations at Amgen will present. ...
May 08, 2020 08:30 am ET
FDA Grants Fast Track Designation for Omecamtiv Mecarbil in Heart Failure
Amgen (NASDAQ:AMGN) and Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for omecamtiv mecarbil, a novel selective cardiac myosin activator, also known as a...
May 08, 2020 08:30 am ET
FDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., May 8, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for omecamtiv mecarbil, a novel selective cardiac myosin activator, also known as a cardiac myotrope,1 being developed for the potential treatment of chronic heart failure with reduced ejection fraction (HFrEF). ...
May 06, 2020 09:00 am ET
Amgen Announces Positive Top-Line Results From Otezla® (apremilast) Phase 3 ADVANCE Study In Mild-To-Moderate Plaque Psoriasis
THOUSAND OAKS, Calif., May 6, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive top-line results from the ADVANCE trial, a Phase 3, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy of Otezla® (apremilast) in adults with mild-to-moderate plaque psoriasis. The study showed that oral Otezla 30 mg twice daily achieved a statistically significant improvement, compared with placebo, in the primary endpoint of the static Physician's Global Assessment (sPGA) response (defined as an sPGA score of clear (0) or almost clear (1) with at least a 2-poi...
May 05, 2020 09:00 am ET
KYPROLIS® (carfilzomib) Patents Upheld Against Generic Manufacturer
THOUSAND OAKS, Calif., May 5, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. District Court in Delaware issued a decision upholding the validity of patent claims from three patents that protect Amgen's multiple myeloma therapy KYPROLIS® (carfilzomib). Today's decision will prevent Cipla Limited, and Cipla USA, Inc. (collectively "Cipla") from making, using, selling, offering to sell, or importing its generic version of KYPROLIS until expiration of these three U.S. patents. The latest patent expiry is in December 2027. ...
May 04, 2020 04:15 pm ET
Amgen To Present At The SunTrust Robinson Humphrey Life Sciences Summit Virtual Meeting Series
THOUSAND OAKS, Calif., May 4, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Company will participate in the SunTrust Robinson Humphrey Life Sciences Summit Virtual Meeting Series. David M. Reese, M.D., executive vice president of Research and Development at Amgen, is scheduled to participate on Wednesday, May 6 at 11:00 a.m. PT (2:00 p.m. ET).  ...
Apr 30, 2020 04:01 pm ET
Amgen Reports First Quarter 2020 Financial Results
THOUSAND OAKS, Calif., April 30, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2020 and discussed the company's response to the COVID-19 pandemic....
Apr 27, 2020 04:01 pm ET
Amgen Announces Webcast Of 2020 First Quarter Financial Results
THOUSAND OAKS, Calif., April 27, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Thursday, April 30, 2020, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2:30 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team....
Apr 14, 2020 05:21 pm ET
Iceland Provides a Picture of the Early Spread of COVID-19 in a Population with a Cohesive Public Health Response
REYKJAVIK, Iceland, April 14, 2020 /PRNewswire/ -- Scientists at deCODE genetics and colleagues from Iceland's Directorate of Health and the National University Hospital today publish online in the New England Journal of Medicine a population-based study of the early spread of the SARS-Cov-2 virus (causing COVID-19 disease) in Iceland. The aim of the study was to provide as comprehensive a view as possible of how the virus spreads in a population, in this case one of 360,000 and implementing early and aggressive testing, tracking and isolation measures to contain the epidemic. The results sh...
Apr 07, 2020 08:35 pm ET
Amgen And Adaptive Biotechnologies To Participate In Webinar On COVID-19 Strategic Collaboration
THOUSAND OAKS, Calif., and SEATTLE, April 7, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Adaptive Biotechnologies Corporation (NASDAQ:ADPT) will participate in a webinar hosted by Bernstein on Thursday, April 9 at 8 a.m. PT (11 a.m. ET) where David M. Reese, M.D., executive vice president of Research and Development at Amgen and Harlan Robins, PhD, chief scientific officer and co-founder at Adaptive, will discuss the companies' strategic collaboration to develop a therapeutic to prevent or treat COVID-19.  ...
Apr 02, 2020 09:00 am ET
Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19
THOUSAND OAKS, Calif., and SEATTLE, April 2, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Adaptive Biotechnologies (NASDAQ:ADPT) today announced a collaboration aimed at helping address the COVID-19 pandemic. The companies will combine expertise to discover and develop fully human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19. The mutually exclusive collaboration brings together Adaptive's proprietary immune medicine platform for the identification of virus-neutralizing antibodies with Amgen's expertise in immunology and novel antibody therapy developm...
Mar 31, 2020 08:00 pm ET
Amgen Establishes Wholly-Owned Affiliate In Japan
THOUSAND OAKS, Calif., March 31, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has consummated the purchase from Astellas of 49% of shares of Amgen Astellas BioPharma K.K. (AABP), a joint venture between Amgen and Astellas established in 2013.  AABP, which is now a wholly-owned Amgen affiliate in Japan renamed Amgen K.K., has enabled Amgen to build a strong presence in Japan as it advances treatments for serious illnesses. ...
Mar 28, 2020 10:00 am ET
Amgen Announces Positive Results At ACC.20/WCC From Phase 3B Study Of Repatha® (Evolocumab) In People Living With HIV Who Have High LDL-Cholesterol
THOUSAND OAKS, Calif., March 28, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive results from the EvolocumaB Effect on LDL-C LowerIng in SubJEcts with Human Immunodeficiency ViRus and INcreased Cardiovascular RisK (BEIJERINCK) study evaluating the efficacy and safety of Repatha® (evolocumab) in patients who are human immunodeficiency virus-positive (HIV+) and have high low-density lipoprotein cholesterol (LDL-C) despite stable background lipid-lowering therapy.1 The study demonstrated that treatment with Repatha significantly reduced LDL-C. The results were featured as an o...
Mar 23, 2020 04:01 pm ET
Amgen And The Amgen Foundation Commit Up To $12.5 Million To Support COVID-19 Relief Efforts
THOUSAND OAKS, Calif., March 23, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and the Amgen Foundation today announced an initial commitment of up to $12.5 million to support U.S. and global relief efforts to address critical needs in communities impacted by the COVID-19 pandemic.  The funds will be used to support emergency response efforts in Amgen's U.S. and international communities, patient-focused organizations that are mounting their own response efforts, and international relief efforts by Direct Relief and International Medical Corps. The Amgen Foundation will also match donations made ...
Feb 26, 2020 08:30 am ET
Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis
Amgen (NASDAQ:AMGN), Cytokinetics, Incorporated (NASDAQ:CYTK) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC-HF recently completed the second and final planned interim analysis, which included consideration of...
Feb 06, 2020 06:00 am ET
Survivors in Canada are Taking Steps to Reduce the Risk of Another Heart Attack. But is it Enough?
New Amgen Survey Shows Heart Attack Survivors in Canada Do Not Know Their Cholesterol Level or What It Should Be ...
Jan 02, 2020 08:15 am ET
BeiGene Announces Closing of Amgen Global Strategic Oncology Collaboration and Equity Investment
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that, following...
Nov 18, 2019 09:00 am ET
New Results From COSMIC-HF Presented at AHA 2019 Show Treatment of Heart Failure Patients With Omecamtiv Mecarbil Was Associated With Neutral or Improved Measures of Diastolic Function
Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier announced that new results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecamtiv...
Nov 11, 2019 08:00 am ET
Amgen Highlights Data To Be Presented At AHA 2019 Across Cardiovascular Portfolio
THOUSAND OAKS, Calif., Nov. 11, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from its cardiovascular portfolio will be presented at the American Heart Association (AHA) Scientific Sessions 2019 in Philadelphia, Nov. 16-18. This includes new clinical and real-world studies that provide further evidence of the benefits of intensive lipid-lowering therapy with Repatha® (evolocumab) as well as new data for omecamtiv mecarbil, a novel selective cardiac myosin activator being developed for the treatment of heart failure with reduced ejection fraction (HFrEF)....
Nov 07, 2019 04:01 pm ET
Amgen To Present At The 28th Annual Credit Suisse Healthcare Conference
THOUSAND OAKS, Calif., Nov. 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 28th Annual Credit Suisse Healthcare Conference at 9:45 a.m. MT on Tuesday, Nov. 12, 2019, in Scottsdale, Ariz. David W. Meline, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event....
Oct 31, 2019 04:00 pm ET
BeiGene Announces Global Strategic Oncology Collaboration with Amgen
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) and Amgen (NASDAQ: AMGN) today announced a global strategic oncology collaboration for the commercialization and development in China of Amgen’s XGEVA® (denosumab), KYPROLIS® (carfilzomib), and BLINCYTO®...
Oct 31, 2019 04:00 pm ET
Amgen Enters Into Strategic Collaboration With BeiGene To Expand Oncology Presence In China
THOUSAND OAKS, Calif., Oct. 31, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that it has entered into a strategic collaboration with BeiGene that will significantly accelerate Amgen's plans to expand its oncology presence in China, the world's second-largest pharmaceutical market. BeiGene is a research-based, oncology-focused biotechnology company with an established and highly experienced team in China, including a 700-person commercial organization and a 600-person clinical development organization. ...
Oct 30, 2019 06:00 pm ET
The Discovery Of Amgen's Novel Investigational KRAS(G12C) Inhibitor AMG 510 Published In Nature
THOUSAND OAKS, Calif., Oct. 30, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a publication in Nature unveiling the discovery of AMG 510, a small molecule inhibitor of KRASG12C being investigated as a treatment for a variety of solid tumors with KRAS G12C mutation. AMG 510 is the first investigational KRASG12C inhibitor to advance to the clinic and is currently enrolling in a potentially registrational Phase 2 study. ...
Oct 29, 2019 04:01 pm ET
Amgen Reports Third Quarter 2019 Financial Results
THOUSAND OAKS, Calif., Oct. 29, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2019. Key results include:...
Oct 24, 2019 04:00 pm ET
Amgen Announces Webcast of 2019 Third Quarter Financial Results
THOUSAND OAKS, Calif., Oct. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Tuesday, Oct. 29, 2019, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team....
Oct 24, 2019 09:00 am ET
Amgen To Make Repatha® (evolocumab) Available Exclusively At Its Lower List Price Option In 2020
THOUSAND OAKS, Calif., Oct. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that effective Dec. 31, 2019, Repatha® (evolocumab), an innovative treatment for patients with high cholesterol and cardiovascular disease proven to reduce heart attacks and strokes, will be distributed exclusively at the 60% lower list price of $5,850 per year and will no longer be available at its original list price. ...
Oct 23, 2019 04:00 pm ET
Amgen Recommends Rejection Of 'Mini-Tender' Offer From TRC Capital Corporation
THOUSAND OAKS, Calif., Oct. 23, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has been notified of an unsolicited "mini-tender" offer dated Oct. 11, 2019, made by TRC Capital Corporation, a private Canadian investment company, to purchase up to 500,000 shares of Amgen's common stock beginning on Oct. 14, 2019. TRC Capital's unsolicited "mini-tender" offer price of $192.00 per share is approximately 4.38% below the $200.80 per share closing price of Amgen's common stock on Oct. 11, 2019, the last trading day prior to the commencement of the offer. Amgen is not affiliated in...
Oct 22, 2019 07:22 pm ET
David Meline, Amgen's Chief Financial Officer, To Retire
THOUSAND OAKS, Calif., Oct. 22, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the planned retirement of David W. Meline, who has served as the company's executive vice president and chief financial officer (CFO) since 2014. Meline will serve as CFO through the end of 2019 and remain at the company into the second quarter of 2020 to help ensure a smooth transition of his responsibilities. The company also announced that Peter H. Griffith has joined Amgen as executive vice president, Finance, and will be Meline's successor as CFO as of Jan. 1, 2020. ...
Oct 22, 2019 04:00 pm ET
Amgen Announces 2019 Fourth Quarter Dividend
THOUSAND OAKS, Calif., Oct. 22, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.45 per share dividend for the fourth quarter of 2019. The dividend will be paid on Dec. 6, 2019, to all stockholders of record as of the close of business on Nov. 15, 2019. ...
Oct 18, 2019 09:00 am ET
Nplate® (romiplostim) Now Approved For Earlier Use In Adults With Immune Thrombocytopenia
THOUSAND OAKS, Calif., Oct. 18, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved Amgen's Supplemental Biologics License Application (sBLA) for Nplate® (romiplostim) to include new data in its U.S. prescribing information showing sustained platelet responses in adults with immune thrombocytopenia (ITP), a rare, serious autoimmune disease characterized by low platelet counts. The updated indication expands treatment with Nplate to newly diagnosed and persistent adult ITP patients who have had an insufficient response to corticos...
Oct 18, 2019 01:00 am ET
EVENITY® (Romosozumab) Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
THOUSAND OAKS, Calif. and BRUSSELS, Oct. 17, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that following a re-examination procedure, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending Marketing Authorization for EVENITY® (romosozumab) for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture and with no history of myocardial infarction or stroke. EVENITY is a novel bone-builder with a dual effect that increases bone formation a...
Oct 15, 2019 09:00 am ET
Sports Anchor And Multiple Myeloma Patient Rod Gilmore Joins Amgen's Myeloma MVP™ Team
THOUSAND OAKS, Calif., Oct. 15, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the expansion of Myeloma MVP™, a national initiative to help myeloma patients and their care teams create their Most Valuable Plan. In its second year, Myeloma MVP now includes an updated tool on MyelomaExplained.com to help patients communicate with their doctors and develop a personal strategy for managing their disease. ...
Oct 09, 2019 09:04 am ET
Amgen Foundation Launches Amgen Biotech Experience In Pittsburgh
THOUSAND OAKS, Calif. and PITTSBURGH, Oct. 9, 2019 /PRNewswire/ -- The Amgen Foundation today announced the launch of the Amgen Biotech Experience (ABE) program in Pittsburgh, Pa. Through a grant from the Richard King Mellon Foundation, the region's students will become a part of the Amgen Foundation's respected international science education program, making it the tenth program site in the United States and the 20th worldwide. ...
Sep 28, 2019 01:00 am ET
Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Patients With Solid Tumors At ESMO 2019
THOUSAND OAKS, Calif., Sept. 27, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C-mutant solid tumors. The data include the first evidence of anti-tumor activity reported in patients with colorectal cancer (CRC) and appendiceal cancer, as well as previously presented non-small cell lung cancer (NSCLC) findings. AMG 510 continues to be well-tolerated with no dose-limiting toxicities. These data are being presented during a poster discussion at the European Society for Medical Onco...
Sep 26, 2019 09:00 am ET
Heart Attack Survivors Are Taking Steps To Reduce Their Cardiovascular Risk. But Are They The Right Ones?
THOUSAND OAKS, Calif., Sept. 26, 2019 /PRNewswire/ -- In recognition of World Heart Day on Sunday, September 29, Amgen (NASDAQ:AMGEN) today released findings from a global survey that evaluated worldwide heart attack survivors' perceptions and awareness of the connection between cholesterol and cardiovascular (CV) events....
Sep 25, 2019 04:00 pm ET
Amgen To Webcast Investor Call At ESMO 2019
THOUSAND OAKS, Calif., Sept. 25, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society for Medical Oncology (ESMO) 2019 Congress on Saturday, Sept. 28, at 10 a.m. PT. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team, will participate to discuss Amgen's oncology program, including data being presented at ESMO for the Company's KRASG12C inhibitor AMG 510.  ...
Sep 24, 2019 04:00 pm ET
Amgen Announces Positive Results From Two Phase 3 BLINCYTO® (blinatumomab) Studies In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia
THOUSAND OAKS, Calif., Sept. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (20120215) showed that the primary endpoint of event-free survival was met. The study evaluated the efficacy, safety and tolerability of BLINCYTO® (blinatumomab) compared to conventional consolidation chemotherapy in pediatric patients with high-risk, B-cell acute lymphoblastic leukemia (ALL) at first relapse. Enrollment was terminated early due to encouraging efficacy in the BLI...
Sep 17, 2019 04:00 pm ET
Amgen Showcases New Data From Oncology Pipeline And Portfolio At ESMO 2019
THOUSAND OAKS, Calif., Sept. 17, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from its oncology pipeline and marketed product portfolio will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain, Sept. 27-Oct. 1, 2019. ...
Sep 16, 2019 11:30 am ET
S&P 500 buybacks decline significantly in Q2 2019; expenditures still remain higher than the pre-2018 levels
NEW YORK, Sept. 16, 2019 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") announced today that preliminary Q2 2019 S&P 500® stock buybacks, or share repurchases, were $164.5 billion. This was the second consecutive quarterly decline after four consecutive quarters of record buybacks. Q2 2019 buybacks were 20.1% lower than Q1 2019's $205.6 billion, 13.7% lower year-over-year from Q2 2018's $190.6 billion, and 26.2% lower than the Q4 2018 record expenditure of $223.0 billion.  ...
Sep 13, 2019 04:00 pm ET
Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference
THOUSAND OAKS, Calif., Sept. 13, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:45 a.m. British Summer Time on Wednesday, Sept. 18, 2019, in London. David W. Meline, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event. ...
Sep 13, 2019 09:00 am ET
Amgen Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) Meets Primary Endpoint Of Progression-Free Survival
THOUSAND OAKS, Calif., Sept. 13, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Phase 3 CANDOR study evaluating KYPROLIS® (carfilzomib) in combination with dexamethasone and DARZALEX® (daratumumab) (KdD) compared to KYPROLIS and dexamethasone alone (Kd) met its primary endpoint of progression-free survival (PFS). The regimen resulted in a 37% reduction in the risk of progression or death in patients with relapsed or refractory multiple myeloma treated with KdD (HR=0.630; 95% CI: 0.464, 0.854; p=0.0014). The median PFS for patients treated with Kd alone was 15.8 months, while th...
Sep 12, 2019 09:00 am ET
Amgen Highlights New Data From KYPROLIS® (carfilzomib) And Oncology Pipeline At IMW 2019
THOUSAND OAKS, Calif., Sept. 12, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from its oncology portfolio and pipeline will be presented at the 17th International Myeloma Workshop (IMW) 2019 in Boston, Sept. 12-15, 2019. ...
Sep 08, 2019 03:45 am ET
Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Larger Patient Group At WCLC 2019
THOUSAND OAKS, Calif., Sept. 8, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C-mutated solid tumors. AMG 510 is a first-in-class investigational oral therapy that is designed to selectively and irreversibly target the KRASG12C protein. The additional follow-up in a larger group of patients with non-small cell lung cancer (NSCLC) continued to show anti-tumor activity with no dose-limiting toxicities. These data are being presented during an oral presentation at IASLC 2019 World C...
Sep 05, 2019 04:00 pm ET
Amgen To Present At The Morgan Stanley Global Healthcare Conference
THOUSAND OAKS, Calif., Sept. 5, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Morgan Stanley Global Healthcare Conference at 9:10 a.m. ET on Tuesday, Sept. 10, 2019, in New York City. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event. ...
Sep 04, 2019 04:00 pm ET
Amgen To Webcast Investor Call At IASLC 2019 World Conference on Lung Cancer
THOUSAND OAKS, Calif., Sept. 4, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community at the International Association for the Study of Lung Cancer (IASLC) 2019 World Conference on Lung Cancer (WCLC) on Sunday, Sept. 8, at 8 a.m. PT. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team, will participate to discuss Amgen's oncology program, including data being presented at WCLC for the Company's KRASG12C inhibitor AMG 510.  ...
Aug 28, 2019 09:00 am ET
New Amgen Data To Be Presented At ESC Congress 2019 Highlight Additional Evidence For Repatha® (Evolocumab) Effectiveness In Cardiovascular Disease Across Multiple Patient Groups
THOUSAND OAKS, Calif., Aug. 28, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the presentation of 14 cardiovascular scientific research abstracts, including studies evaluating the safety and efficacy of Repatha® (evolocumab) by race and ethnicity and further examining its clinical benefit in patients with familial hypercholesterolemia (FH).1,2 The data will be presented at ESC Congress 2019, organized by the European Society of Cardiology, in Paris, Aug. 31–Sept. 4....
Aug 26, 2019 06:30 am ET
Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits
THOUSAND OAKS, Calif., Aug. 26, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced today that it has entered into an agreement with Celgene Corporation (NASDAQ: CELG) in connection with its previously announced merger with Bristol-Myers Squibb Company (NYSE: BMY) to acquire worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, and certain related assets and liabilities, for $13.4 billion in cash, or approximately $11.2 billion, net of the present value of $2.2 billion in anticipated future cash tax benefits. Amgen believ...
Aug 22, 2019 09:00 am ET
Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (Rituximab)
THOUSAND OAKS, Calif., Aug. 22, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798, a biosimilar candidate to Rituxan® (rituximab), compared to Rituxan in patients with CD20-positive B-cell non-Hodgkin's lymphoma. The primary endpoint, an assessment of overall response rate (ORR) by week 28, was within the prespecified margin for ABP 798 compared to Rituxan, showing clinical equivalence. Safety and immunogenicity of ABP 798 were comparable to Rituxan. ...
Aug 09, 2019 04:05 pm ET
Amgen Wins Patent Case On Enbrel® (etanercept)
THOUSAND OAKS, Calif., Aug. 9, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. District Court for the District of New Jersey has ruled in Amgen's favor on validity of the two patents that describe and claim Enbrel® (etanercept) and methods for making it....
Aug 02, 2019 04:00 pm ET
Amgen Announces 2019 Third Quarter Dividend
THOUSAND OAKS, Calif., Aug. 2, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.45 per share dividend for the third quarter of 2019. The dividend will be paid on Sept. 6, 2019, to all stockholders of record as of the close of business on Aug. 15, 2019.  ...
Jul 30, 2019 04:01 pm ET
Amgen Reports Second Quarter 2019 Financial Results
THOUSAND OAKS, Calif., July 30, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the second quarter of 2019. Key results include:...
Jul 26, 2019 04:00 pm ET
Jul 25, 2019 04:00 pm ET
Amgen Announces Webcast Of 2019 Second Quarter Financial Results
THOUSAND OAKS, Calif., July 25, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Tuesday, July 30, 2019, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2:30 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team....
Jul 18, 2019 11:00 pm ET
Amgen And Allergan's MVASI™ (bevacizumab-awwb) And KANJINTI™ (trastuzumab-anns) Now Available In The United States
THOUSAND OAKS, Calif., July 18, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that MVASI™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), and KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin® (trastuzumab), are now available in the United States (U.S.). ...
Jul 11, 2019 04:30 pm ET
Amgen, Novartis And Banner Alzheimer's Institute Discontinue Clinical Research Program With BACE Inhibitor CNP520 For Alzheimer's Prevention
THOUSAND OAKS, Calif., July 11, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN), Novartis and Banner Alzheimer's Institute today announced the collective decision to discontinue investigation of the BACE1 inhibitor CNP520 (umibecestat) in two pivotal Phase 2/3 studies in the Alzheimer's Prevention Initiative Generation Program. An assessment of unblinded data during a regular pre-planned review identified worsening in some measures of cognitive function. The sponsors concluded that the potential benefit for participants in the studies did not outweigh the risk. ...
Jun 05, 2019 07:00 am ET
Amgen Announces First Clinical Data Evaluating Investigational KRAS(G12C) inhibitor AMG 510 at ASCO 2019
AMG 510 is the First KRASG12C Inhibitor to Reach Clinical Stage After Three Decades of RAS Research...
Jun 05, 2019 07:00 am ET
Amgen Highlights the Versatility of the BiTE® Immuno-Oncology Platform in Multiple Tumour Types at ASCO 2019
Updated Phase 1 Data of Investigational AMG 420 in Relapsed and/or Refractory Multiple Myeloma Highlighted in Oral Presentation and Accepted for Best of ASCO®...
May 22, 2019 02:00 am ET
Amgen announces a recommended public cash offer to the shareholders of Nuevolution
THOUSAND OAKS, Calif., May 21, 2019 /PRNewswire/ --...
May 21, 2019 04:00 pm ET
Amgen Announces Voting Results Of Annual Meeting Of Stockholders
THOUSAND OAKS, Calif., May 21, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village, Calif. Approximately 89 percent of outstanding shares were represented at the meeting. ...
May 16, 2019 04:00 pm ET
Amgen To Present At The RBC Healthcare Conference And The UBS Global Healthcare Conference
THOUSAND OAKS, Calif., May 16, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the RBC Health Care Conference at 8:30 a.m. ET and at the UBS Global Healthcare Conference at 2 p.m. ET on Tuesday, May 21, 2019, in New York City. Elliott M. Levy, M.D., senior vice president of Global Development at Amgen, will present at both conferences. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event....
May 15, 2019 05:07 pm ET
Amgen Showcases Oncology Pipeline At ASCO 2019
THOUSAND OAKS, Calif., May 15, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that data from its oncology pipeline will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2019. Seven investigational assets will be featured across a range of hematologic malignancies and solid tumors....
May 10, 2019 04:00 pm ET
Amgen To Present At The Bank of America Merrill Lynch 2019 Health Care Conference
THOUSAND OAKS, Calif., May 10, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch 2019 Health Care Conference at 10 a.m. PT on Wednesday, May 15, 2019. David W. Meline, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event....
May 02, 2019 04:30 pm ET
Amgen To Highlight Extensive Long-Term Safety And Efficacy Data Of Aimovig® (erenumab-aooe) Across The Spectrum Of Migraine At AAN Annual Meeting
THOUSAND OAKS, Calif., May 2, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present new long-term data of Aimovig® (erenumab-aooe) across the migraine spectrum at the 2019 American Academy of Neurology (AAN) Annual Meeting in Philadelphia. Data from a one-year open-label extension (OLE) trial following a three-month double blind study in patients with chronic migraine (15 or more headache days per month) showed sustained efficacy and safety in this patient population, including a potential for conversion to episodic migraine (4-14 headache days a month). Additionally,...
May 02, 2019 04:00 pm ET
Amgen And Syapse Enter Precision Medicine Collaboration In Oncology
THOUSAND OAKS, Calif. and SAN FRANCISCO, May 2, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN), a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, today announced a precision medicine collaboration in oncology....
May 01, 2019 04:00 pm ET
Amgen Ignites A Social Fitness Movement To Support The Fight Against Heart Disease And Cancer
THOUSAND OAKS, Calif., May 1, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today launched the Breakaway Challenge initiative, a national social fitness program to motivate individuals to take action in their health and to support the fight against heart disease and cancer. Amgen's Breakaway Challenge joins together Breakaway from Cancer® and Breakaway from Heart Disease™ and serves as a complementary component to its title sponsorship of the Amgen Tour of California, a world-class cycling event that takes place May 12 – 18, 2019. ...
Apr 30, 2019 04:01 pm ET
Amgen Reports First Quarter 2019 Financial Results
THOUSAND OAKS, Calif., April 30, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2019. Key results include:...
Apr 25, 2019 04:00 pm ET
Amgen Announces Webcast of 2019 First Quarter Financial Results
THOUSAND OAKS, Calif., April 25, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Tuesday, April 30, 2019, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team....
Apr 17, 2019 04:00 pm ET
Amgen Foundation Launches Amgen Biotech Experience In Tampa, Florida
TAMPA, Fla., April 17, 2019 /PRNewswire/ -- The Amgen Foundation, together with the University of South Florida (USF), today announced the launch of the Amgen Biotech Experience (ABE) program in Tampa, Florida, as part of its long-standing science education program. Globally, ABE is expected to reach nearly 900,000 secondary school students by 2020 in 20 regions around the world....
Apr 15, 2019 04:00 pm ET
EVENITY™ (romosozumab-aqqg) Now Available In The United States For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
THOUSAND OAKS, Calif., April 15, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that EVENITY™ (romosozumab-aqqg) is now available for shipment to wholesalers in the U.S. EVENITY was approved by the U.S. Food and Drug Administration (FDA) on April 9, 2019, for the treatment of osteoporosis in postmenopausal women at high risk for fracture. ...
Apr 09, 2019 03:57 pm ET
FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
THOUSAND OAKS, Calif. and BRUSSELS, April 9, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has approved EVENITY™ (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture. EVENITY is the first and only bone builder with a unique dual effect that both increases bone formation and to a lesser extent reduces bone resorption (or bone loss) to rapidly reduce the risk of fracture. A full course of EVENITY therapy is 12 monthly doses administered by a healthcare...
Apr 07, 2019 05:00 am ET
Amgen Presents New Data At WCO-IOF-ESCEO 2019 Revealing Osteoporosis Treatment Gap In Europe
THOUSAND OAKS, Calif., April 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data presented from a cross-sectional study revealing a gap in the diagnosis and treatment of osteoporosis in Europe. The real-world study of osteoporosis management in primary care revealed that 75 percent of female patients aged 70 years and older who were at increased risk of fragility fractures were not treated for osteoporosis. The treatment gap was much lower in those with a recorded diagnosis of osteoporosis than in those without a recorded diagnosis. The results of the study, which was perfor...
Mar 26, 2019 07:50 am ET
New Research Coverage Highlights Amgen, Alarm, Werner Enterprises, Churchill Downs, Markel, and AAR — Consolidated Revenues, Company Growth, and Expectations for 2019
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Amgen Inc. (NASDAQ:AMGN), Alarm.com Holdings, Inc. (NASDAQ:ALRM), Werner...
Mar 25, 2019 10:53 am ET
S&P 500 Q4 2018 Buybacks Set 4th Consecutive Quarterly Record at $223 Billion; 2018 Sets Record $806 Billion
NEW YORK, March 25, 2019 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") announced today that preliminary Q4 2018 S&P 500® stock buybacks, or share repurchases, set a fourth consecutive record of $223.0 billion. This displaces the previous record of $203.8 billion, set during Q3 2018 and is a 62.8% increase from the $137.0 billion reported for Q4 2017. ...
Mar 20, 2019 08:30 am ET
Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
THOUSAND OAKS, Calif., and SOUTH SAN FRANCISCO, Calif., and SURESNES, France, March 20, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC-HF recently completed the first planned interim analysis, which included consideration of pre-specified criteria for futility. The DMC reviewed data from GALACTIC-HF and recommended that this Phase 3 clinical trial of omecamtiv mecarbil continue without changes to its conduct.  ...
Mar 20, 2019 08:30 am ET
Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis
Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC-HF recently completed the first planned interim analysis, which included consideration of...
Mar 15, 2019 04:00 pm ET
Amgen Announces New Four-Year Outcomes Study To Examine Long-Term Effects Of Repatha® (evolocumab) In High-Risk Cardiovascular Disease (CVD) Patients Without Prior Heart Attack Or Stroke
THOUSAND OAKS, Calif., March 15, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced plans to conduct VESALIUS-CV, a multinational clinical outcomes study for Repatha® (evolocumab) which will involve at least 13,000 patients worldwide at high risk of experiencing a first cardiovascular (CV) event, despite optimized treatment with lipid-lowering therapy.1 The study will be the first to investigate long-term outcomes in this population with Repatha for a minimum of four years.1 ...
Mar 12, 2019 09:29 am ET
Amgen and Jay Leno Partner to Sound the Alarm on High Cholesterol and its Link to Heart Attack and Stroke in Patients Most at Risk
THOUSAND OAKS, Calif., March 12, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today launched Cholesterol 911, a national initiative urging high-risk cardiovascular disease patients to reduce their risk of another heart attack or stroke by addressing their continued high LDL-C, or "bad" cholesterol. Comedian and television host Jay Leno has partnered with Amgen to motivate patients and caregivers to get in the driver's seat as it relates to their cholesterol management. Leno's familiar humor and love of cars are at the forefront of this message. A series of videos set in Leno's famous garage soun...
Mar 07, 2019 03:05 pm ET
Amgen Announces 2019 Second Quarter Dividend
THOUSAND OAKS, Calif., March 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.45 per share dividend for the second quarter of 2019. The dividend will be paid on June 7, 2019, to all stockholders of record as of the close of business on May 17, 2019. ...
Mar 07, 2019 03:00 pm ET
Amgen To Present At The Cowen and Company 39th Annual Healthcare Conference
THOUSAND OAKS, Calif., March 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Cowen and Company 39th Annual Healthcare Conference at 9:20 a.m. ET on Tuesday, March 12, 2019, in Boston. David W. Meline, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event....
Mar 06, 2019 03:00 pm ET
New Data From Amgen To Be Presented At ACC.19 Continues To Build Evidence For Repatha® (evolocumab) Across Multiple Patient Populations
THOUSAND OAKS, Calif., March 6, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of nine cardiovascular scientific research abstracts, including safety and efficacy results from the largest and longest open label study of homozygous familial hypercholesterolemia (HoFH) patients (TAUSSIG),1  as well as a sub-analysis from the Repatha® (evolocumab) cardiovascular outcomes study (FOURIER). Additional abstracts to be presented include real-world evidence (RWE) findings from the GOULD registry demonstrating suboptimal care for high-risk cardiovascular disease (CVD) patien...
Mar 05, 2019 07:30 am ET
New Research: Key Drivers of Growth for Marsh & McLennan Companies, Conagra Brands, Amgen, Emerson Electric, Polaris Industries, and Hologic — Factors of Influence, Major Initiatives and Sustained Pro
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Marsh & McLennan Companies, Inc. (NYSE:MMC), Conagra Brands Inc....
Feb 28, 2019 03:00 pm ET
Amgen Highlights Progress Of Innovative Early Oncology Pipeline With New Data At AACR 2019
THOUSAND OAKS, Calif., Feb. 28, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from its early-stage oncology pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, March 29 – April 3, 2019. ...
Feb 25, 2019 03:56 pm ET
Jury Upholds Amgen's Patents On Repatha® (evolocumab)
THOUSAND OAKS, Calif., Feb. 25, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that a Delaware jury delivered a verdict in Amgen's favor upholding the validity of two Amgen patents related to PCSK9 antibodies. These patents describe and claim antibodies, like Amgen's innovative Repatha® (evolocumab) product, that bind to a specific region on PCSK9 and reduce LDL-C levels in the body. This verdict follows a previous trial in March 2016 where Sanofi and Regeneron admitted infringement of Amgen's patents and where a prior jury also upheld the validity of Amgen's patents. The prior jur...
Feb 25, 2019 08:05 am ET
Prominent Cardiovascular Expert, James J. Ferguson, M.D., FACC, FAHA Joins Matinas BioPharma as Chief Medical Officer
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has appointed a prominent cardiovascular medical and clinical development expert, James (“Terry”) J. Ferguson, M.D., FACC, FAHA,...
Feb 21, 2019 08:30 am ET
Amgen, Cytokinetics and Servier Announce Start of METEORIC-HF, the Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), the second Phase 3...
Feb 21, 2019 07:30 am ET
Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
THOUSAND OAKS, Calif., SOUTH SAN FRANCISCO, Calif., and SURESNES, France, Feb. 21, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), the second Phase 3 clinical trial of omecamtiv mecarbil, a novel cardiac myosin activator, is open to enrollment. Omecamtiv mecarbil is being developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF)....
Feb 01, 2019 08:00 am ET
Factors of Influence in 2019, Key Indicators and Opportunity within Marathon Oil, Accuray, United Natural Foods, Systemax, Amgen, and NewLink Genetics — New Research Emphasizes Economic Growth
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Marathon Oil Corporation (NYSE:MRO), Accuray Incorporated...
Jan 29, 2019 03:01 pm ET
Amgen Reports Fourth Quarter And Full Year 2018 Financial Results
THOUSAND OAKS, Calif., Jan. 29, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2018 in comparison to comparable periods in 2017. Key results include:...
Jan 24, 2019 03:30 pm ET
Amgen Announces Webcast of 2018 Fourth Quarter and Full Year Financial Results
THOUSAND OAKS, Calif., Jan. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2018 financial results on Tuesday, Jan. 29, 2019, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team....
Jan 24, 2019 03:00 pm ET
Amgen Receives NMPA Approval For Repatha® (evolocumab) In China To Reduce The Risk Of Cardiovascular Events
THOUSAND OAKS, Calif., Jan. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the National Medical Products Administration (NMPA) has approved a new indication for Repatha® (evolocumab) as the first PCSK9 inhibitor in China for adults with established atherosclerotic cardiovascular disease (ASCVD) to reduce the risk of myocardial infarction, stroke and coronary revascularization....
Jan 24, 2019 08:00 am ET
Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab
THOUSAND OAKS, Calif., Jan. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a Phase 1/ Phase 3 study evaluating the pharmacokinetics, efficacy and safety of biosimilar candidate ABP 798, a biosimilar candidate to RITUXAN® (rituximab), compared to rituximab in patients with moderate-to-severe rheumatoid arthritis. The results demonstrate that the study met its primary endpoint of pharmacokinetic (PK) similarity. Additionally, equivalent efficacy was established and a similar safety profile was demonstrated....
Jan 22, 2019 08:00 am ET
European Commission Approves BLINCYTO® (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia
THOUSAND OAKS, Calif., Jan. 22, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved an expanded indication for BLINCYTO® (blinatumomab) monotherapy to include adult patients with Philadelphia chromosome negative (Ph-) CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1 percent. The approval was based on data from the Phase 2 BLAST study in frontline and relapsed/refractory ALL, the largest prospective trial for MRD-positive A...
Jan 16, 2019 04:41 pm ET
Amgen And UCB Receive Positive Vote From FDA Advisory Committee In Favor Of Approval For EVENITY™ (romosozumab)
THOUSAND OAKS, Calif. and BRUSSELS, Jan. 16, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced strong support from the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) for the approval of EVENITY™* (romosozumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture after reviewing safety and efficacy data from the pivotal Phase 3 studies. Eighteen of 19 members voted yes for approval. In their discussion, the Committee emphasized the need for post-marketing follow-...
Jan 08, 2019 03:00 pm ET
EVENITY™ (romosozumab) Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture
THOUSAND OAKS, Calif. and BRUSSELS, Belgium, Jan. 8, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the Japanese Ministry of Health, Labor and Welfare has granted a marketing authorization for EVENITY™ (romosozumab) for the treatment of osteoporosis in patients at high risk of fracture.1 Amgen and UCB are co-developing EVENITY worldwide, with development in Japan being led by Amgen Astellas BioPharma K.K., a joint venture between Amgen and Astellas Pharma Inc., headquartered in Tokyo. ...
Jan 07, 2019 03:00 pm ET
Amgen Makes All Repatha® (evolocumab) Device Options Available In The US At A 60 Percent Reduced List Price
THOUSAND OAKS, Calif., Jan. 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that as part of the Company's commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and strokes, all Repatha® (evolocumab) device options, including the Pre-Filled Syringe and Pushtronex® (on-body infusor with prefilled cartridge), are now available at a 60 percent reduced list price of $5,850 per year. The most commonly used delivery system, the Repatha SureClick® autoinjector, was made available at the lower lis...
Jan 07, 2019 07:25 am ET
Report: Exploring Fundamental Drivers Behind Spectrum Brands, Amgen, MSCI, Diamondback Energy, Centene, and Paramount Group — New Horizons, Emerging Trends, and Upcoming Developments
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Spectrum Brands Holdings Inc. (NYSE:SPB), Amgen Inc. (NASDAQ:AMGN), MSCI...
Jan 03, 2019 03:00 pm ET
Amgen To Present At The 37th Annual J.P. Morgan Healthcare Conference
THOUSAND OAKS, Calif., Jan. 3, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 37th Annual J.P. Morgan Healthcare Conference at 8:30 a.m. PT on Tuesday, Jan. 8, 2019, in San Francisco. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event. ...
Dec 19, 2018 03:00 pm ET
Amgen Submits Supplemental Biologics License Application For Nplate® (romiplostim)
THOUSAND OAKS, Calif., Dec. 19, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Nplate® (romiplostim) to include the treatment of adult patients with immune thrombocytopenia (ITP) who have had ITP for 12 months or less and an insufficient response to corticosteroids, immunoglobulins or splenectomy....
Dec 18, 2018 10:00 pm ET
Amgen And Molecular Partners Announce Strategic Collaboration In Immuno-Oncology
THOUSAND OAKS, Calif. and ZURICH-SCHLIEREN, Switzerland, Dec. 18, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics, today announced a collaboration and license agreement for the clinical development and commercialization of MP0310 (FAP x 4-1BB). MP0310 is a preclinical molecule designed to locally activate immune cells in the tumor by binding to FAP on tumor stromal cells (localizer) and co-stimulating T cells via 4-1BB (immune modulator). ...
Dec 18, 2018 03:00 pm ET
Amgen Engages Cambridge Biotech Community To Select 2018 LabCentral Golden Ticket Winners
CAMBRIDGE, Mass., Dec. 18, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and LabCentral today announced that Kernal Biologics and PanTher Therapeutics have each won the Amgen Golden Ticket at LabCentral. The two Golden Ticket winners were chosen by an Amgen internal committee and live audience members at a "Quick Pitch" event hosted by Amgen at its Cambridge, Mass. facility on Dec. 11, 2018. Six finalists pitched their business plans to attendees where the audience members' votes served as input for the Amgen internal committee's decision. ...
Dec 18, 2018 10:00 am ET
S&P 500 Q3 2018 Buybacks Surpass $200 Billion Mark for the First Time Ever
NEW YORK, Dec. 18, 2018 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") announced today that preliminary Q3 2018 S&P 500® stock buybacks, or share repurchases, surpassed the $200 billion mark for the first time to set a record $203.8 billion. This is the third consecutive record, displacing the prior quarterly record of $190.6 billion, set during Q2 2018 and a 57.7% increase from the $129.2 billion reported for Q3 2017. For the first three quarters of 2018, buybacks are up 52.6% to $583.4 billion from the prior year's $382.4 billion, and stand 1% away from the annual re...
Dec 17, 2018 08:00 am ET
Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration
THOUSAND OAKS, Calif., Dec. 17, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 710, a biosimilar candidate to REMICADE® (infliximab). ...
Dec 14, 2018 03:00 pm ET
FDA Approves Nplate® (Romiplostim) For Use In Pediatric Patients With Immune Thrombocytopenia
THOUSAND OAKS, Calif., Dec. 14, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Nplate® (romiplostim) for the treatment of pediatric patients one year of age and older with immune thrombocytopenia (ITP) for at least six months who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. ...
Dec 13, 2018 03:00 pm ET
Amgen And Direct Relief Partner To Aid Cancer Patients In 18 Developing Countries
THOUSAND OAKS, Calif. and SANTA BARBARA, Calif., Dec. 13, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Direct Relief today announced a joint initiative in which Direct Relief will distribute $93 million worth of Amgen donated cancer treatments and supportive care medicines. This donation will provide cancer patients in 18 developing countries access to Neulasta® (pegfilgrastim), NEUPOGEN® (filgrastim) and Vectibix® (panitumumab). ...
Dec 11, 2018 03:00 pm ET
Amgen And Magellan Rx Management Collaborate To Improve Patient Care For Chronic, Difficult-To-Treat Conditions
THOUSAND OAKS, Calif., Dec. 11, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced a novel multi-year collaboration with Magellan Rx Management, the pharmacy benefit management division of Magellan Health, that will leverage each company's capabilities and resources to identify clinical gaps for some of the healthcare system's most difficult-to-treat diseases. Based on Amgen and Magellan's extensive expertise in complex areas of health and specialty populations, the initial projects will focus on improving patient outcomes for the treatment of osteoporosis and migraine. These projects ...
Dec 10, 2018 03:41 pm ET
Amgen And Lazarex Cancer Foundation Team Up To Allow More Diversity In Clinical Trials
THOUSAND OAKS, Calif. and SAN FRANCISCO, Dec. 10, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and the Lazarex Cancer Foundation, a non-profit organization focused on improving patient access to cancer clinical trials, today announced that they have teamed up to support more equitable access to clinical trials for cancer patients in the U.S. Through a corporate donation, Amgen has contributed $2 million to Lazarex's IMPACT (IMproving Patient Access to Cancer Clinical Trials) program, which is focused on improving patient enrollment, retention, minority participation and equitable access in oncol...
Dec 07, 2018 03:00 pm ET
Amgen Announces 10 Percent Increase In 2019 First Quarter Dividend
THOUSAND OAKS, Calif., Dec. 7, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.45 per share dividend for the first quarter of 2019. The dividend will be paid on March 8, 2019, to all stockholders of record as of the close of business on Feb. 15, 2019. This represents a 10 percent increase from that paid in each of the previous four quarters....
Dec 03, 2018 08:15 pm ET
Amgen Announces First-In-Human Data Evaluating Investigational Novel BiTE® Immunotherapies AMG 420 And AMG 330 At ASH 2018
THOUSAND OAKS, Calif., Dec. 3, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the first clinical results from studies evaluating investigational novel bispecific T cell engager (BiTE®) immunotherapies AMG 420 and AMG 330. In two separate Phase 1 dose escalation studies, AMG 420, which targets B-cell maturation antigen (BCMA), and AMG 330, which targets CD33, provided early evidence of tolerability and anti-tumor activity in patients with relapsed and/or refractory multiple myeloma and relapsed or refractory acute myeloid leukemia (AML), respectively. These data were highlighted dur...
Dec 03, 2018 03:00 pm ET
Amgen To Present At The Citi Global Healthcare Conference
THOUSAND OAKS, Calif., Dec. 3, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Citi Global Healthcare Conference at 12:35 p.m. ET on Thursday, Dec. 6, 2018, in New York City. Elliott M. Levy, M.D., senior vice president of Global Development at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event. ...
Nov 30, 2018 03:00 pm ET
Amgen And UCB Announce FDA Advisory Committee Meeting To Review EVENITY™ (romosozumab) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
THOUSAND OAKS, Calif. and BRUSSELS, Nov. 30, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) will review data supporting the Biologics License Application (BLA) for EVENITYTM (romosozumab) for the treatment of osteoporosis in postmenopausal women at high risk for fracture at a meeting on Jan. 16, 2019. ...
Nov 29, 2018 08:40 am ET
Research Report Identifies Equinix, Universal Electronics, LHC Group, Cohbar, Amgen, and Aetna with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Equinix, Inc. (NASDAQ:EQIX), Universal Electronics Inc. (NASDAQ:UEIC),...
Nov 28, 2018 03:00 pm ET
Amgen To Webcast Investor Call At ASH 2018
THOUSAND OAKS, Calif., Nov. 28, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition on Monday, Dec. 3, 2018, at 8 p.m. PT. David M. Reese, M.D., executive vice president of Research and Development at Amgen, together with other members of Amgen's management team and a clinical investigator, will participate to discuss data presented at ASH and the Company's oncology program, including the bispecific T Cell engager (BiTE®) immuno-oncology platform. ...
Nov 21, 2018 03:00 pm ET
Amgen To Present At the Piper Jaffray And Evercore ISI Healthcare Conferences
THOUSAND OAKS, Calif., Nov. 21, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Piper Jaffray Healthcare Conference at 8:30 a.m. ET on Tuesday, Nov. 27, 2018, in New York City and at the Evercore ISI Healthcare Conference at 11 a.m. ET on Wednesday, Nov. 28, 2018, in Boston. Elliott M. Levy, M.D., senior vice president of Global Development at Amgen, will present at the conferences. Live audio of each presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of each webcast will also be available on Amgen's website for at ...
Nov 16, 2018 08:00 am ET
Amgen Receives CHMP Positive Opinion To Expand Use Of BLINCYTO® (Blinatumomab) In Patients With Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
THOUSAND OAKS, Calif., Nov. 16, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to expand the current indication for BLINCYTO® (blinatumomab) monotherapy to include adult patients with Philadelphia chromosome negative CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1 percent. The application included data from the Phase 2 BLAST study i...
Nov 12, 2018 03:00 pm ET
Amgen Presents Results Highlighting The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In The Longest Duration Study Of A PCSK9 Inhibitor To Date At AHA Scientific Sessions 2018
THOUSAND OAKS, Calif., Nov. 12, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the final report of the Open-Label Study of Long-TERm Evaluation Against LDL-C (OSLER-1), demonstrating long-term treatment with Repatha® (evolocumab) was associated with robust and consistent reductions in low-density lipoprotein cholesterol (LDL-C), with no increase in overall rates of adverse events over time and no neutralizing antibodies. Additionally, data from the Getting to an ImprOved Understanding of Low-Density Lipoprotein and Dyslipidemia Management (GOULD) Registry reflect a disconnect betwe...
Nov 12, 2018 08:00 am ET
Amgen Foundation Pledges $500,000 In Relief To Victims Of Ventura And Los Angeles County Wildfires
THOUSAND OAKS, Calif., Nov. 12, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Amgen Foundation has pledged $500,000 to support victims of the local wildfires in Ventura and Los Angeles Counties. The Amgen Foundation will select recipient non-profit organizations based on relief effort needs. In addition, the Amgen Foundation has committed $250,000 to the Ventura County Community Foundation's Conejo Valley Victims Fund to support the victims, families and organizations providing support after the recent Thousand Oaks shooting tragedy. ...
Nov 05, 2018 03:00 pm ET
Amgen Announces Presentation Of Research Reinforcing The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In High-Risk Patients At AHA Scientific Sessions 2018
THOUSAND OAKS, Calif., Nov. 5, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of 10 scientific research abstracts, including the final report of the OSLER-1 study, evaluating the long-term safety and efficacy of Repatha® (evolocumab) in patients with hypercholesterolemia for up to five years. Additional abstracts to be presented include a sub-analysis of the Repatha cardiovascular outcomes study (FOURIER), investigating the effects of triglycerides on cardiovascular risk in patients with established cardiovascular disease, and an evaluation of the utilization of li...
Nov 05, 2018 08:00 am ET
Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease
THOUSAND OAKS, Calif. and OLDWICK, N.J., Nov. 5, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Provention Bio, Inc. (NASDAQ:PRVB), a clinical-stage biopharmaceutical company focused on immune-mediated diseases, today announced a licensing and co-development agreement for AMG 714, identified by Provention as PRV-015. AMG 714 is a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease (NRCD). Development efforts at Provention will be led by researchers with previous experience developing AMG 714. ...
Nov 01, 2018 04:00 pm ET
Amgen To Present New Data Showcasing Extensive Portfolio And Exciting Early Oncology Pipeline At ASH 2018
THOUSAND OAKS, Calif., Nov. 1, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new clinical data will be presented at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego, Dec. 1-4, 2018. Data across an array of malignancies will be featured in 45 abstracts, including nine oral presentations, from the Company's broad portfolio and early-stage pipeline....
Nov 01, 2018 09:00 am ET
Amgen Foundation Deepens Commitment To Aspiring Scientists Worldwide By Expanding Amgen Scholars Program
THOUSAND OAKS, Calif., Nov. 1, 2018 /PRNewswire/ -- The Amgen Foundation today announced the expansion of the Amgen Scholars Program, a hands-on research program that allows undergraduates to spend a summer at one of many of the world's premier research institutions. The new four-year, $21 million commitment brings the program to a total of 24 elite institutions across the U.S., Europe, Asia and, for the first time, Australia and Canada. Over the next four years an additional 1,500 undergraduates from hundreds of colleges and universities will have the chance to engage in research opportunit...
Oct 30, 2018 04:01 pm ET
Amgen Reports Third Quarter 2018 Financial Results
THOUSAND OAKS, Calif., Oct. 30, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2018. Key results include:...
Oct 26, 2018 07:54 pm ET
Amgen Announces New FOURIER Analysis Showing Benefit With Repatha® (Evolocumab) In High-Risk Patients With Established Cardiovascular Disease And Chronic Kidney Disease
THOUSAND OAKS, Calif., Oct. 26, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha® (evolocumab) in patients with established cardiovascular disease by kidney function. In line with previous FOURIER subgroup analyses, these results further demonstrate Repatha's efficacy in reducing not only low-density lipoprotein cholesterol (LDL-C) levels, but also the relative risk for major cardiovascular events such as heart attack and stroke, in high-risk patients including those with mild-to-moderate...
Oct 26, 2018 04:00 pm ET
Amgen Announces Webcast Of 2018 Third Quarter Financial Results
THOUSAND OAKS, Calif., Oct. 26, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2018 financial results on Tuesday, Oct. 30, 2018, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team....
Oct 24, 2018 04:00 pm ET
Amgen Makes Repatha® (Evolocumab) Available In The US At A 60 Percent Reduced List Price
THOUSAND OAKS, Calif., Oct. 24, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it is making Repatha® (evolocumab), an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and strokes, available at a reduced list price of $5,850 per year. This 60 percent reduction from the medicine's original list price will improve affordability by lowering patient copays, especially for Medicare patients....
Oct 24, 2018 09:00 am ET
First Head-to-Head Trial of a TNF Inhibitor Versus Methotrexate Monotherapy in Psoriatic Arthritis Shows ENBREL® (Etanercept) Monotherapy and Combination Therapy Both Superior to Methotrexate
THOUSAND OAKS, Calif., Oct. 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that positive results from the Phase 3 SEAM-PsA study comparing the efficacy of Enbrel® (etanercept) monotherapy and ENBREL plus methotrexate to methotrexate monotherapy in patients with psoriatic arthritis (PsA) were presented in a late-breaking poster session at the 2018 American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting in Chicago, Oct. 19-24, 2018. ...
Oct 23, 2018 04:00 pm ET
Amgen Announces 2018 Fourth Quarter Dividend
THOUSAND OAKS, Calif., Oct. 23, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.32 per share dividend for the fourth quarter of 2018. The dividend will be paid on Dec. 7, 2018, to all stockholders of record as of the close of business on Nov. 16, 2018. ...
Oct 22, 2018 09:00 am ET
Data Projects the Global Biotechnology Market Will Continue to Grow
NEW YORK, October 22, 2018 /PRNewswire/ --...
Oct 19, 2018 07:20 am ET
Investor Expectations to Drive Momentum within Amgen, Crown Castle International, Constellation Brands, Nice, NetEase, and The Hanover Insurance Group — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amgen Inc. (NASDAQ:AMGN), Crown Castle International Corporation...
Oct 18, 2018 09:00 am ET
Amgen Invests £50 Million ($66 Million) In Oxford Nanopore Technologies
THOUSAND OAKS, Calif. and OXFORD, England, Oct. 18, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Oxford Nanopore Technologies Ltd. today announced Amgen's equity investment of £50 million ($66 million) in Oxford Nanopore, a privately-owned, UK-based company advancing a new generation of portable, real-time genetic sequencing technology. ...
Oct 16, 2018 12:00 am ET
Amgen Launches AMGEVITA™ (Biosimilar Adalimumab) In Markets Across Europe
THOUSAND OAKS, Calif., Oct. 15, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that AMGEVITATM, a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018. AMGEVITA is the first adalimumab biosimilar to be approved by the European Commission (EC). AMGEVITA is authorized for the treatment of inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis (AS); severe axial spondyloarthritis without radiographic evidence of AS; moderate-to-severe chronic plaque psoriasis; mo...
Oct 01, 2018 09:00 am ET
FDA Approves KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
THOUSAND OAKS, Calif., Oct. 1, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to expand the Prescribing Information for KYPROLIS® (carfilzomib) to include a once-weekly dosing option in combination with dexamethasone (once-weekly Kd70) for patients with relapsed or refractory multiple myeloma. The approval is based on data from the Phase 3 A.R.R.O.W. trial, which demonstrated that KYPROLIS administered once-weekly at 70 mg/m2 with dexamethasone achieved superior progression-fr...
Sep 24, 2018 09:00 pm ET
BLINCYTO® (blinatumomab) Approved In Japan For The Treatment Of Relapsed Or Refractory B-cell Acute Lymphoblastic Leukemia
THOUSAND OAKS, Calif., Sept. 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for BLINCYTO® (blinatumomab) for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). BLINCYTO was developed in Japan by Amgen Astellas BioPharma K.K. (AABP), a joint venture between Amgen and Astellas Pharma Inc., a pharmaceutical company headquartered in Tokyo. ...
Sep 24, 2018 10:01 am ET
S&P 500 Q2 2018 Buybacks Increase 58.7% Year-Over-Year to Record $190.6 Billion
NEW YORK, Sept. 24, 2018 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") today announced preliminary results indicating that S&P 500® stock buybacks, or share repurchases, totaled $190.6 billion for Q2 2018, displacing the prior quarterly record of $189.1 billion, set during Q1 2018. This is a 58.7% increase from the $120.1 billion reported for Q2 2017. For the first half of 2018, buybacks are up 49.9% to $379.7 billion from the prior year's $253.3 billion....
Sep 20, 2018 09:00 am ET
Amgen And Los Angeles County Announce Collaboration To Support Life Science Innovation Hub - BioLA
THOUSAND OAKS, Calif. and LOS ANGELES, Sept. 20, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and the County of Los Angeles today announced that Amgen has agreed to become a founding sponsor of BioLA, a newly formed organization focused on advancing a life science innovation hub in Los Angeles County. The innovation hub is designed to contribute to advancements in global health by strengthening the County's life sciences ecosystem and accelerating the pace of startup activity. BioLA will also focus on creating jobs, driving economic development and promoting the County's public healthcare system...
Sep 17, 2018 04:30 pm ET
World's Largest Alzheimer's Survey Reveals Most Adults Believe a Cure Will be Developed in Their Lifetime
THOUSAND OAKS, Calif., Sept. 17, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN), Novartis and Banner Alzheimer's Institute (BAI), in association with Alzheimer's Disease International (ADI), today announced results from the largest global survey to date investigating perceptions of Alzheimer's disease. Findings show that most adults (62 percent) are worried they may develop Alzheimer's, while nearly the same proportion believe it is likely a cure will be developed in their lifetime (60 percent).1 This World Alzheimer's Month, Amgen, Novartis, BAI and ADI are raising awareness about how volunteers ...
Sep 11, 2018 04:00 pm ET
Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference
THOUSAND OAKS, Calif., Sept. 11, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9 a.m. GMT on Friday, Sept. 14, 2018, in London. David W. Meline, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event. ...
Sep 07, 2018 04:00 pm ET
Amgen To Present At The Morgan Stanley Global Healthcare Conference
THOUSAND OAKS, Calif., Sept. 7, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Morgan Stanley Global Healthcare Conference at 9:20 a.m. ET on Wednesday, Sept. 12, 2018, in New York City. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event. ...
Sep 07, 2018 02:00 am ET
Tezepelumab Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Severe Asthma Without An Eosinophilic Phenotype
THOUSAND OAKS, Calif., Sept. 6, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma without an eosinophilic phenotype. ...
Sep 05, 2018 09:00 am ET
Amgen And LabCentral Open Nomination Process For Lab Residency
CAMBRIDGE, Mass., Sept. 5, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and LabCentral today announced that the nomination process to submit proposals to receive an Amgen-sponsored LabCentral Golden Ticket is open for interested life sciences and biotech startup companies. LabCentral is an innovative, shared laboratory space designed as a launchpad for premier high-impact life sciences and biotech startups. As one of LabCentral's platinum sponsors, Amgen can nominate up to two early-stage companies each year to take up residence in LabCentral's Kendall Square facilities in Cambridge, Mass. ...
Aug 29, 2018 09:00 am ET
European Commission Approves BLINCYTO® (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
THOUSAND OAKS, Calif., Aug. 29, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved an expanded indication for BLINCYTO® (blinatumomab) as monotherapy for the treatment of pediatric patients aged one year or older with Philadelphia chromosome-negative CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL), which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation. The approval is based on results from the Phase 1/2 '205 stu...
Aug 27, 2018 09:00 am ET
Amgen Submits Supplemental New Drug Application For KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone
THOUSAND OAKS, Calif., Aug. 27, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the Prescribing Information for KYPROLIS® (carfilzomib) to include a once-weekly dosing option in combination with dexamethasone (Kd) for patients with relapsed or refractory multiple myeloma. The sNDA is based on data from the Phase 3 A.R.R.O.W. trial, demonstrating KYPROLIS administered once-weekly at 70 mg/m2 with dexamethasone (once-weekly Kd) achieved superior progression-free surviv...
Aug 21, 2018 08:00 am ET
Amgen To Present Robust Data Exploring The Impact Of Treatment With Repatha® (evolocumab) Across Patient Subgroups And High-Risk Populations At ESC Congress 2018
THOUSAND OAKS, Calif., Aug. 21, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the upcoming presentation of new Repatha® (evolocumab) analyses, including a late-breaking study evaluating the efficacy of Repatha in patients with metabolic syndrome and established cardiovascular disease at the ESC Congress 2018, organized by the European Society of Cardiology, in Munich, Aug. 25-29. ...
Jul 31, 2018 04:15 pm ET
Amgen Breaks Ground On Next-Generation Biomanufacturing Plant In Rhode Island
THOUSAND OAKS, Calif., July 31, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the groundbreaking of its new next-generation biomanufacturing plant that will be constructed at its West Greenwich, R.I. campus. The new plant is the first-of-its-kind in the U.S. and will use Amgen's proven next-generation biomanufacturing capabilities to manufacture products for the U.S. and global markets....
Jul 31, 2018 04:00 pm ET
Amgen Announces 2018 Third Quarter Dividend
THOUSAND OAKS, Calif., July 31, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.32 per share dividend for the third quarter of 2018. The dividend will be paid on Sept. 7, 2018, to all stockholders of record as of the close of business on Aug. 17, 2018. ...
Jul 26, 2018 04:02 pm ET
Amgen Announces Succession Plans For Two Executive Officers
THOUSAND OAKS, Calif., July 26, 2018 /PRNewswire/ -- As part of Amgen's (NASDAQ:AMGN) planned executive succession to address upcoming retirements, the Company announced transition plans for two of its executive vice presidents today....
Jul 26, 2018 04:01 pm ET
Amgen Reports Second Quarter 2018 Financial Results
THOUSAND OAKS, Calif., July 26, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2018. Key results include:...
Jul 24, 2018 04:00 pm ET
Amgen Announces Webcast of 2018 Second Quarter Financial Results
THOUSAND OAKS, Calif., July 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter 2018 financial results on Thursday, July 26, 2018, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team....
Jul 19, 2018 04:00 pm ET
Amgen And Cedars-Sinai Partner For Improved Healthcare Quality
THOUSAND OAKS, Calif. and LOS ANGELES, July 19, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Cedars-Sinai Medical Center today announced a partnership to help support the improvement of healthcare quality in the treatment of multiple therapeutic areas that could include oncology, cardiovascular disease, osteoporosis and migraine. The organizations intend to jointly undertake research projects in one or more of these therapeutic areas. They also plan to focus on projects that could achieve better clinical outcomes, experience and patient satisfaction....
Jul 18, 2018 09:00 am ET
Former Major League Baseball (MLB) All-Stars Dave Winfield And Steve Garvey Team Up With Amgen To Launch Myeloma MVP™ And Encourage Patients To Create Their Most Valuable Plan For Managing Multiple My
THOUSAND OAKS, Calif., July 18, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the launch of Myeloma MVPTM, a national campaign to help those affected by multiple myeloma create their Most Valuable Plan, an individualized approach for managing their disease. Multiple myeloma is an incurable blood cancer for which there are a variety of treatment options, requiring patients to work closely with their doctors to determine the right plan to meet their needs. ...
Jul 13, 2018 01:00 am ET
Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY™ (romosozumab) To The US FDA
THOUSAND OAKS, Calif. and BRUSSELS, July 12, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced the resubmission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for EVENITY™* (romosozumab), an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at high risk for fracture. EVENITY increases bone formation and reduces bone resorption simultaneously to increase bone mineral density (BMD) and reduce the risk of fracture....
Jun 27, 2018 05:00 pm ET
Amgen And Health And Benefits Consultant Piper Jordan Partner On First Migraine Project With Employers
THOUSAND OAKS, Calif. and SAN DIEGO, June 27, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Piper Jordan, one of the nation's leading health and benefits consulting firms, today announced a unique partnership to help improve health and well-being in the workplace for people living with migraine. The collaboration aims to provide disease management resources to both the employee and employer through innovative educational programs, including well-being initiatives for those living with migraine. This marks the first Amgen partnership with an employee benefit consultant (EBC) and is Amgen's fir...
Jun 27, 2018 04:30 pm ET
Amgen And Novartis Highlight Findings From A Large Global Patient Survey Revealing That Worldwide Approximately 60 Percent Of Employed People With Migraine Missed, On Average, A Week Of Work In A Mont
THOUSAND OAKS, Calif., June 27, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced initial findings from a large global migraine patient survey, involving more than 11,000 people from 31 countries, including the U.S. The findings, to be presented at the 60th Annual Scientific Meeting of the American Headache Society (AHS) in San Francisco, reveal that migraine is associated with overall work and activity impairment.1 On average, 60 percent of employed respondents worldwide missed almost a full working week (4.6 days) due to migraine in a month.1 Migraine is a distinct neurological dise...
Jun 27, 2018 09:00 am ET
Amgen Announces Top-Line Results From Phase 3 Study Of ABP 710, Biosimilar Candidate To Infliximab
THOUSAND OAKS, Calif., June 27, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 710 compared with REMICADE® (infliximab) in patients with moderate-to-severe rheumatoid arthritis. The results confirm non-inferiority compared to infliximab but could not rule out superiority based on its primary efficacy endpoint, which compared the response difference measured by 20 percent or greater improvement defined by the American College of Rheumatology (ACR) Criteria, ACR20, at week 22. Key secondary en...
Jun 23, 2018 08:00 am ET
New Data Show Amgen's Repatha® (evolocumab) Significantly Reduced LDL-C And Non-HDL-C In High-risk Patients With Type 2 Diabetes
THOUSAND OAKS, Calif., June 23, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data that show Repatha® (evolocumab) significantly reduced low-density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (non-HDL-C) in patients with Type 2 diabetes and hypercholesterolemia or mixed dyslipidemia, taking the maximum tolerated dose of moderate/high-intensity statin therapy. BANTING was a dedicated study evaluating the efficacy of Repatha (monthly dosing), in lowering LDL-C and improving other lipid levels in patients with Type 2 diabetes.1 In addition to mee...
Jun 19, 2018 09:00 am ET
Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO® (blinatumomab) Label
THOUSAND OAKS, Calif., June 19, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted a full marketing authorization for BLINCYTO® (blinatumomab) based on the overall survival (OS) data from the Phase 3 TOWER study in adult patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)....
Jun 12, 2018 08:25 am ET
Research Report Identifies Avangrid, Entercom Communications, Kennedy-Wilson, Emerson Electric, Amgen, and vTv Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Avangrid, Inc. (NYSE:AGR), Entercom Communications Corporation (NYSE:ETM),...
Jun 11, 2018 09:00 am ET
FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS® (carfilzomib) Label
THOUSAND OAKS, Calif., June 11, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to add the positive overall survival (OS) data from the Phase 3 ASPIRE trial to the U.S. Prescribing Information for KYPROLIS® (carfilzomib). Data added to the label showed that KYPROLIS, lenalidomide and dexamethasone (KRd) significantly reduced the risk of death by 21 percent and extended overall survival by 7.9 months versus lenalidomide and dexamethasone alone (Rd) in patients with relapsed or r...
Jun 08, 2018 08:23 pm ET
/C O R R E C T I O N -- Amgen/
In the news release, Amgen To Present At The Goldman Sachs 39th Annual Global Healthcare Conference, issued 07-Jun-2018 by Amgen over PR Newswire, we are advised by the company that the 1st paragraph, 1st sentence, should read "Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 39th Annual Global Healthcare Conference at 1:20 p.m. PT on Tuesday, June 12, 2018, in Rancho Palos Verdes, Calif." rather than "Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 39th Annual Global Healthcare Conference at 9:30 a.m. PT on Tuesday, June 12, 2018, in Rancho Palos Verdes, Calif." as originally iss...
Jun 08, 2018 09:00 am ET
European Commission Approves Prolia® (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
THOUSAND OAKS, Calif., June 8, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a new indication for Prolia® (denosumab) for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. The EC approval is based on the positive results of a Phase 3 study that evaluated the safety and efficacy of Prolia compared with risedronate in patients receiving glucocorticoid treatment.1 ...
Jun 07, 2018 04:00 pm ET
Amgen To Present At The Goldman Sachs 39th Annual Global Healthcare Conference
THOUSAND OAKS, Calif., June 7, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 39th Annual Global Healthcare Conference at 9:30 a.m. PT on Tuesday, June 12, 2018, in Rancho Palos Verdes, Calif. Elliott M. Levy, M.D., senior vice president of Research and Development at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event. ...
Jun 06, 2018 04:00 pm ET
Amgen, Oklahoma Health Care Authority And University of Oklahoma's Pharmacy Management Consultants Partner To Improve Medicaid Outcomes
THOUSAND OAKS, Calif. and OKLAHOMA CITY, June 6, 2018 /PRNewswire/ -- The Oklahoma Health Care Authority (OHCA), Pharmacy Management Consultants (PMC) and Amgen (NASDAQ:AMGN) today announced a new collaborative agreement to help improve clinical outcomes, experience and satisfaction for Oklahoma's 796,000 SoonerCare (Oklahoma Medicaid) members. Results from the projects also could lay the groundwork for innovative ways to look at patient outcomes and measures for medication reimbursement. ...
Jun 01, 2018 04:00 pm ET
Phase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 mg/m2 KYPROLIS® (carfilzomib) Regimen Significantly Extended Progression-Free Survival Versus A Twice-Weekly 27 mg/m2 Regimen In Patients With
THOUSAND OAKS, Calif., June 1, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the Phase 3 A.R.R.O.W. trial of a once-weekly KYPROLIS® (carfilzomib) dosing regimen in patients with relapsed and refractory multiple myeloma. In the trial, KYPROLIS administered once-weekly at 70 mg/m2 with dexamethasone (once-weekly Kd) achieved superior progression-free survival (PFS) and overall response rates (ORR), with a comparable safety profile, versus twice-weekly KYPROLIS at 27 mg/m2 and dexamethasone (twice-weekly Kd). These data were presented during an oral session at the 54th ...
May 31, 2018 04:00 pm ET
Amgen And MD Anderson Announce Collaboration To Accelerate Early Stage Treatments For Leukemia, Myelodysplastic Syndromes, Multiple Myeloma, Small-Cell Lung And Other Small-Cell Cancers
THOUSAND OAKS, Calif. and HOUSTON, May 31, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and The University of Texas MD Anderson Cancer Center today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen's early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung cancer, and other non-lung cancers with small-cell histologies. The agreements combine Amgen therapies nearing clinical development or those that have already begun the process with MD Anderson's translational medicine capabil...
May 23, 2018 04:00 pm ET
Amgen Enters Groundbreaking Collaboration To Improve Symptom Management During Cancer Treatment
THOUSAND OAKS, Calif., May 23, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced a groundbreaking collaboration with the National Cancer Institute (NCI), the Federal Communications Commission (FCC) Connect2Health Task Force, the University of Kentucky (UK) Markey Cancer Center and the University of California, San Diego (UCSD) Design Lab to support the improvement of cancer outcomes. The L.A.U.N.C.H. (Linking & Amplifying User-Centered Networks through Connected Health) program will use human-centered design methodologies to identify the needs of patients, caregivers and healthcar...
May 21, 2018 04:00 pm ET
FDA Approves Prolia® (Denosumab) For Glucocorticoid-Induced Osteoporosis
THOUSAND OAKS, Calif., May 21, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the use of Prolia® (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. This approval is based on data from a Phase 3 study which showed patients on glucocorticoid therapy who received Prolia had greater gains in...
May 17, 2018 07:04 pm ET
FDA Approves Aimovig™ (erenumab-aooe), A Novel Treatment Developed Specifically For Migraine Prevention
THOUSAND OAKS, Calif., May 17, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Aimovig™ (erenumab-aooe) for the preventive treatment of migraine in adults. Aimovig is a novel therapeutic approach as the first and only FDA-approved treatment specifically developed to prevent migraine by blocking the calcitonin gene-related peptide receptor (CGRP-R) – which is believed to play a critical role in migraine. Aimovig 70 mg is self-administered once monthly via Amgen's device, the SureClick® autoinjector, and does not require a...
May 16, 2018 09:00 am ET
Amgen Receives European Commission Approval For Repatha® (Evolocumab) To Prevent Heart Attack And Stroke In Adults With Established Cardiovascular Disease
THOUSAND OAKS, Calif., May 16, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a new indication in the Repatha® (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL-C) levels. With the expanded label now in place, Amgen is working with payers in Europe to remove prescribing barriers and expand access in order to reach patients with established cardiovascular di...
May 10, 2018 04:45 pm ET
Amgen To Present At The Bank of America Merrill Lynch 2018 Health Care Conference
THOUSAND OAKS, Calif., May 10, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch 2018 Health Care Conference at 10 a.m. PT on Tuesday, May 15, 2018. David W. Meline, executive vice president and chief financial officer at Amgen, and David M. Reese, senior vice president of Translational Sciences and Oncology at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90...
Apr 30, 2018 09:00 am ET
Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS® (carfilzomib) Label
THOUSAND OAKS, Calif., April 30, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a label variation for KYPROLIS® (carfilzomib) to include the final overall survival (OS) data from the Phase 3 ASPIRE trial. The ASPIRE trial demonstrated that the addition of KYPROLIS to lenalidomide and dexamethasone (KRd) reduced the risk of death by 21 percent versus lenalidomide and dexamethasone alone (Rd) and extended OS by 7.9 months in patients with r...
Apr 27, 2018 09:00 am ET
Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia® (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis
THOUSAND OAKS, Calif., April 27, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of Prolia® (denosumab) for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture....
Apr 24, 2018 04:01 pm ET
Amgen Reports First Quarter 2018 Financial Results
THOUSAND OAKS, Calif., April 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2018. Key results include:...
Apr 19, 2018 04:00 pm ET
Amgen Announces Webcast Of 2018 First Quarter Financial Results
THOUSAND OAKS, Calif., April 19, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2018 financial results on Tuesday, April 24, 2018, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team....
Apr 17, 2018 04:00 pm ET
Amgen Presents First-Of-Its-Kind Data At AAN Annual Meeting Reinforcing Robust And Consistent Efficacy Of Aimovig™ (erenumab) For Migraine Patients With Multiple Treatment Failures
THOUSAND OAKS, Calif., April 17, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced full results from the Phase 3b LIBERTY trial of Aimovig™ (erenumab) in episodic migraine patients who had previously failed two to four preventive treatments, due to lack of efficacy or to intolerable side effects.1 The data, which will be presented at the 70th Annual Meeting of the American Academy of Neurology (AAN) in Los Angeles, show the potential of Aimovig as an effective preventive treatment option for these patients, who have tried several treatment options without gaining relief. Aimovig is t...
Apr 10, 2018 12:07 pm ET
Amgen Announces Rhode Island Will Be Location Of First US Next-Generation Biomanufacturing Plant
THOUSAND OAKS, Calif., April 10, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced plans to build a new state-of-the-art next-generation biomanufacturing plant at its campus in West Greenwich, R.I. The new plant, the first of its kind in the United States (U.S.), will employ Amgen's proven next-generation biomanufacturing capabilities and manufacture products for the U.S. and global markets....
Apr 09, 2018 04:00 pm ET
Amgen To Present New Pre-Clinical Data Showcasing Robust Approach To Evaluating Potential Anti-Cancer Therapies At AACR 2018
THOUSAND OAKS, Calif., April 9, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new pre-clinical data for several of its novel investigational oncology candidates will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, April 14-18, 2018. Data spans Amgen's early pipeline, including the first presentation of data for its most advanced chimeric antigen receptor (CAR) T cell therapy programs, targeting DLL3 in small cell lung cancer and FLT3 in acute myeloid leukemia (AML). In addition, pre-clinical data for Amgen's DLL3 CAR T cell thera...
Apr 03, 2018 01:00 am ET
European Commission Approves Expanded Indication For Amgen's XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
THOUSAND OAKS, Calif., April 2, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved an expanded indication for XGEVA® (denosumab) for the prevention of skeletal-related events in adults with advanced malignancies involving bone. The indication now covers patients with bone metastases from solid tumors and those with multiple myeloma. The approval is based on data from the Phase 3 '482 study, the largest international trial ever conducted for the prevention of skeletal-related events in multiple myeloma patients....
Mar 29, 2018 03:17 pm ET
FDA Approves BLINCYTO® (blinatumomab) To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children
THOUSAND OAKS, Calif., March 29, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BLINCYTO® (blinatumomab) for the treatment of adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1 percent. This indication is approved under accelerated approval based on MRD response rate and hematological relapse-free survival (RFS). Continued approval for t...
Mar 23, 2018 08:44 am ET
Amgen Receives Positive CHMP Opinion Recognizing That Repatha® (evolocumab) Prevents Heart Attacks And Strokes
THOUSAND OAKS, Calif., March 23, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to include a new indication in the Repatha® (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels. The recommended label recognizes the positive findings from the Repatha cardiovascular outcomes study (FOURIER) and includes d...
Mar 23, 2018 08:41 am ET
Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin®) For The Treatment Of Three Types Of Cancer
THOUSAND OAKS, Calif., March 23, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of ABP 980, a biosimilar to Herceptin® (trastuzumab). ABP 980 has been recommended for approval for the treatment of the same three types of cancer as Herceptin is approved for in the European Union (EU), including HER2-positive metastatic breast cancer, HER2-positive early breast cancer and HER2-positive metasta...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.